Transforming Cancer Immunotherapy: Integration of Distinct Immune-Based Approaches

Strategic Insights -

Researchers from China have detailed a novel concept in cancer treatment, integrating two distinct immunotherapeutic modalities to overcome the limitations of current therapies. The approach, known as Dual Distinct Immunotherapy (DDI), strategically combines different treatments to achieve a synergistic effect. This review highlights the potential of DDI in enhancing therapeutic outcomes for diverse cancer types.

Key Takeaways:

  • The DDI approach involves integrating two distinct immunotherapeutic modalities, including immune checkpoint inhibitors (ICIs), oncolytic viruses (OVs), adoptive cell therapies (CAR-T/TIL), cancer vaccines, or cytokine therapies.
  • The combination of these treatments demonstrates unique synergistic mechanisms and enhanced therapeutic potential through multi-faceted immune activation.
  • The review evaluates emerging candidates, including PCNA inhibitors, HDAC inhibitors, and carbonic anhydrase inhibitors, which can modulate the tumor microenvironment and enhance immunotherapy responses.
  • The DDI + 1 approach targets alternative pathways to overcome resistance mechanisms and expand treatment efficacy to traditionally immunotherapy-resistant cancers.
  • The framework proposes innovative solutions and future research directions for cancer immunotherapy.
  • The authors aim to guide future research and clinical applications in cancer immunotherapy.

Statistics:

  • 2025: The year the research was published.
  • 14(1):114: The volume and page number of the journal Experimental Hematology & Oncology where the study was published.
  • 4 Crinan St, London N1 9XW, England: The address of the journal publisher, BMC.
  • 618000: The postal code of the Deyang People's Hospital, where Cheng Jiang is affiliated.

Sources:

  • Experimental Hematology & Oncology, 2025;14(1):114
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England
  • Cheng Jiang et al. Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer. Experimental Hematology & Oncology, 2025;14(1):114.
  • Vaccine Weekly, October 15, 2025; p 69.